Abstract:Background Amyotrophic lateral sclerosis (ALS) is a disease that causes progressive degeneration of neurons present in the spinal cord and cerebral cortex. It is a disease with a progressive course, with worsening disability and death 3 to 5 years after diagnosis. However, some patients seem to have a slower progression, while others maintain a rapid progression, which may influence the clinical course of the disease and accelerate death. Objectives To evaluate the survival time of patients with ALS, according to the progression of the disease in rapid or slow, and to compare the level of functionality between two evaluations. Methods A longitudinal case series study that followed patients with a confirmed diagnosis of ALS from August 2018 to February 2022. Data were collected from medical records of periodic evaluations, in which pulmonary function tests were performed and the ALS Functional Assessment Scale (ALSFRS-r) was applied. From the values obtained in the scale, the progression rate was calculated, where the patients were divided into slow or rapid progression and followed for 3.5 years for statistical analysis of survival, later performed by the Kaplan-Meyer test. The results of the scores of the first and second evaluation of each patient were compared using the paired t-test. Results 11 patients were followed, 7 with rapid progression (63%) and 4 slow (37%) with a mean age of 61.64 years and forced vital capacity (FVC): 62.2 (38.7-85.7)%pred. In the functionality evaluation, it was observed that there was a significant reduction (p<0.01) in the total scale score compared to the first evaluation. The survival percentage was 0%, where all patients died at the end of the study, but the median survival of the slow progression group from the first evaluation until the final outcome was 46 months, while the rapid progression group was 28 months, with no significant difference between the survival curves (HR = 0.42; CI 0.12 - 1.48). Conclusion The present study was able to demonstrate that after the second evaluation ALS patients may have significant losses of functionality by the decline of the ALSFRS-r functional score. Also, it can determine the evolution of the disease and assist in identifying the speed of progression of the pathology. Implications Regular use of the ALS functional assessment scale and calculation of the rate of progression in the outpatient clinical setting becomes essential to chart a better short- and long-term prognosis and follow-up of the disease.

The primary structure of electric ray hemoglobin (Torpedo marmorata). Bohr effect and phosphate interaction.

Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis

Exploring Advancements in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review of Current Modalities and Future Prospects

Advancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosis

Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury.

Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies

Pathophysiology, Diagnosis, and Therapeutic Advances

Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis

ANALYSIS OF SURVIVAL TIME AND FUNCTIONAL PROGRESSION IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: A LONGITUDINAL STUDY

Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis

Current Therapy in Amyotrophic lateral sclerosis (ALS): a review on Past and Future Therapeutic Strategies

Progress in clinical diagnosis of amyotrophic lateral sclerosis

Re-focusing HIV prevention messages: a qualitative study in rural Uganda

Contribution of neurophysiology to the diagnosis and monitoring ALS

Moulds of understanding. A pattern of natural philosophy

Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis; clinical features, differential diagnosis and pathology

A multidimensional scaling approach to the perception of art. I.

Improving clinical trial outcomes in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies